Therabron Therapeutics
2007
FOUNDED
PRIVATE
STATUS
1-10
EMPLOYEES
Conv. Debt
LATEST DEAL TYPE
$2.33M
LATEST DEAL AMOUNT
3
INVESTORS
Description
Developer of novel drugs with therapeutic proteins designed to cure respiratory diseases. The company's novel drugs with therapeutic proteins develop a series of recombinant human secretoglobins, enabling patients to access treatments for a range of orphan and more commonplace respiratory diseases impacting people from infancy through adulthood.
Website
Formerly Known As
Clarassance
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Pharmaceuticals
Primary Office
- 9430 Key West Avenue
- Suite 150
- Rockville, MD 20850
- United States
+1 (240) 000-0000
Request full access to PitchBook
You’re viewing a free company profile from the PitchBook Platform. To explore Therabron Therapeutics’s full profile, request a free trial.
Therabron Therapeutics Valuation and Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 5. Convertible Debt | 27-Dec-2016 | $2.33M | 00.000 | Completed | Clinical Trials - Phase 2 | |
| 4. Later Stage VC (Series B) | 18-Nov-2015 | 00.00 | 00.000 | 000.00 | Completed | Generating Revenue |
| 3. Grant | 24-Sep-2012 | 00000 | 00000 | Completed | Startup | |
| 2. Angel (individual) | 17-Sep-2012 | $250K | $565K | Completed | Startup | |
| 1. Angel (individual) | 10-Nov-2011 | $315K | $315K | Completed | Startup |
Therabron Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|---|---|---|---|---|---|---|---|
| Series B | 000,000 | 00.000000 | 000.00 | 000.00 | 00 | 000.00 | 00.000 | |
| Series A4 | 0,000 | 00.000000 | 000 | 000 | 00 | 000 | 0.000 | |
| Series A3 | 00,000 | 00.000000 | 00 | 00 | 00 | 00 | 0.000 | |
| Series A2 | 89,683 | $0.001000 | $6.3 | $6.3 | 1x | $6.3 | 2.2% | |
| Series A1 | 116,279 | $0.001000 | $2.15 | $2.15 | 1x | $2.15 | 2.85% |
Therabron Therapeutics Investors (3)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Board Seat |
Contact Info |
|---|---|---|---|---|---|---|
| Brace Pharma Capital | Corporate Venture Capital | Minority | 000 0000 | 000000 0 | ||
| Zell Biotech Two | Other | Minority | 000 0000 | 000000 0 | ||
| United States Army Medical Research Acquisition Activity (USAMRAA) | Government | 000 0000 | 000000 0 |
Therabron Therapeutics Executive Team (6)
| Name | Title | Board Seat |
Contact Info |
|---|---|---|---|
| Aprile Pilon Ph.D | Founder, Chief Scientific Officer, Executive Vice President & Board Member |
5 Former Executives
You’re viewing 1 of 6 executives. Get the full list »Therabron Therapeutics Board Members (7)
| Name | Representing | Role | Since | Contact Info |
|---|---|---|---|---|
| Aprile Pilon Ph.D | Therabron Therapeutics | Founder, Chief Scientific Officer, Executive Vice President & Board Member | 000 0000 | |
| Blanche Johnson Ph.D | Self | Board Member | 000 0000 | |
| Christine Copple Ph.D | Self | Board Member | 000 0000 | |
| Eric Richman | Self | Board Member | 000 0000 | |
| Jeffrey Zell | Self | Board Member | 000 0000 |